Targeting of microRNAs for therapeutics

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Targeting of microRNAs for therapeutics. / Stenvang, Jan; Lindow, Morten; Kauppinen, Sakari.

In: Biochemical Society Transactions, Vol. 36, No. Pt 6, 2008, p. 1197-200.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stenvang, J, Lindow, M & Kauppinen, S 2008, 'Targeting of microRNAs for therapeutics', Biochemical Society Transactions, vol. 36, no. Pt 6, pp. 1197-200. https://doi.org/10.1042/BST0361197

APA

Stenvang, J., Lindow, M., & Kauppinen, S. (2008). Targeting of microRNAs for therapeutics. Biochemical Society Transactions, 36(Pt 6), 1197-200. https://doi.org/10.1042/BST0361197

Vancouver

Stenvang J, Lindow M, Kauppinen S. Targeting of microRNAs for therapeutics. Biochemical Society Transactions. 2008;36(Pt 6):1197-200. https://doi.org/10.1042/BST0361197

Author

Stenvang, Jan ; Lindow, Morten ; Kauppinen, Sakari. / Targeting of microRNAs for therapeutics. In: Biochemical Society Transactions. 2008 ; Vol. 36, No. Pt 6. pp. 1197-200.

Bibtex

@article{96f7b410040f11deb05e000ea68e967b,
title = "Targeting of microRNAs for therapeutics",
abstract = "miRNAs (microRNAs) comprise a class of small endogenous non-coding RNAs that post-transcriptionally repress gene expression by base-pairing with their target mRNAs. Recent evidence has shown that miRNAs play important roles in a wide variety of human diseases, such as viral infections, cancer and cardiovascular diseases, and thus miRNAs have rapidly emerged as potential targets for therapeutics. LNAs (locked nucleic acids) comprise a class of bicyclic conformational analogues of RNA, which exhibit high binding affinity to complementary RNA molecules and high stability in blood and tissues in vivo. Recent reports on LNA-mediated miRNA silencing in rodents and primates support the potential of LNA-modified oligonucleotides in studying miRNA functions in vivo and in the future development of miRNA-based therapeutics.",
author = "Jan Stenvang and Morten Lindow and Sakari Kauppinen",
note = "Keywords: Animals; Disease; Humans; Mice; MicroRNAs; Oligonucleotides; Primates",
year = "2008",
doi = "10.1042/BST0361197",
language = "English",
volume = "36",
pages = "1197--200",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "Pt 6",

}

RIS

TY - JOUR

T1 - Targeting of microRNAs for therapeutics

AU - Stenvang, Jan

AU - Lindow, Morten

AU - Kauppinen, Sakari

N1 - Keywords: Animals; Disease; Humans; Mice; MicroRNAs; Oligonucleotides; Primates

PY - 2008

Y1 - 2008

N2 - miRNAs (microRNAs) comprise a class of small endogenous non-coding RNAs that post-transcriptionally repress gene expression by base-pairing with their target mRNAs. Recent evidence has shown that miRNAs play important roles in a wide variety of human diseases, such as viral infections, cancer and cardiovascular diseases, and thus miRNAs have rapidly emerged as potential targets for therapeutics. LNAs (locked nucleic acids) comprise a class of bicyclic conformational analogues of RNA, which exhibit high binding affinity to complementary RNA molecules and high stability in blood and tissues in vivo. Recent reports on LNA-mediated miRNA silencing in rodents and primates support the potential of LNA-modified oligonucleotides in studying miRNA functions in vivo and in the future development of miRNA-based therapeutics.

AB - miRNAs (microRNAs) comprise a class of small endogenous non-coding RNAs that post-transcriptionally repress gene expression by base-pairing with their target mRNAs. Recent evidence has shown that miRNAs play important roles in a wide variety of human diseases, such as viral infections, cancer and cardiovascular diseases, and thus miRNAs have rapidly emerged as potential targets for therapeutics. LNAs (locked nucleic acids) comprise a class of bicyclic conformational analogues of RNA, which exhibit high binding affinity to complementary RNA molecules and high stability in blood and tissues in vivo. Recent reports on LNA-mediated miRNA silencing in rodents and primates support the potential of LNA-modified oligonucleotides in studying miRNA functions in vivo and in the future development of miRNA-based therapeutics.

U2 - 10.1042/BST0361197

DO - 10.1042/BST0361197

M3 - Journal article

C2 - 19021524

VL - 36

SP - 1197

EP - 1200

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - Pt 6

ER -

ID: 10826288